GlassScriptPhysician profile
David Greenwood
NPI 1033160544
$2,118.88
in general payments reported to CMS, 2019-2025
28 companies · $519 in 2025
The $519 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $135 · 2021: $162 · 2022: $273 · 2023: $269 · 2024: $217 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $222.80 | 2019-2024 | Recarbrio, Zerbaxa, Dificid |
| Stryker Corporation | $183.93 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $182.47 | 2021-2024 | Airsupra, Breztri, Fasenra |
| Abbvie INC. | $178.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $171.11 | 2019-2025 | Nucala |
| Grifols USA, LLC | $140.95 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $113.00 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $96.07 | 2022-2024 | Yupelri |
| United Therapeutics Corporation | $94.19 | 2019-2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.44 | 2020-2023 | Ofev |
| Verona Pharma, INC. | $75.81 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $62.53 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $61.56 | 2019 | |
| Viatris Specialty LLC | $56.23 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $51.56 | 2019-2023 | Nuzyra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $47.43 | 2022-2025 | Vest Therapy Und |
| Insmed, INC. | $40.46 | 2022-2023 | Arikayce |
| Intuitive Surgical, INC. | $33.34 | 2024 | |
| Shire North American Group INC | $30.53 | 2019 | |
| Genentech USA, INC. | $30.24 | 2019 | |
| Circassia INC. | $28.01 | 2019 | |
| Harmony Biosciences LLC | $26.36 | 2021 | |
| Mallinckrodt Hospital Products INC. | $20.53 | 2020 | |
| Advanced Respiratory, INC | $19.44 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.87 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $15.41 | 2025 | |
| Baxter Healthcare | $14.05 | 2024 | Hillrom - Monarch Airway Clearance System |
| 3b Medical, INC. | $11.78 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Greenwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.